|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
University of Zurich ImVision AG |
| Information provided by: | University of Zurich |
| ClinicalTrials.gov Identifier: | NCT00620880 |
Purpose
Primary objective of the trial:
To determine at which concentration the fusion protein MAT Fel d1 degranulates basophils of cat dander allergic patients, in comparison to a cat dander extract and to Fel d1 alone
| Condition | Intervention |
|
Allergy to Cats |
Behavioral: Blood sample |
| MedlinePlus related topics: | Allergy |
| Study Type: | Observational |
| Study Design: | Prospective |
Eligibility
| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion criteria: 1. Patient with Cat Dander Allergy evidenced by positive history 2. Age: 18 to 75 years
Exclusion criteria: 1. Use of oral corticosteroids, Chromoglycin, Ketotifen, or any immunosuppressive drugs within the last 2 months 2. Psychiatric disorder resulting in malcompliance 3. Neg. IgE to Cat dander
Contacts and Locations
More Information
| Study ID Numbers: | IVN-CAT-001A |
| First Received: | February 11, 2008 |
| Last Updated: | February 11, 2008 |
| ClinicalTrials.gov Identifier: | NCT00620880 |
| Health Authority: | Switzerland: UZurich |
|